Algorae Pharmaceuticals’ (ASX: 1AI) new AI-168 drug combination that partly involves cannabidiol has shown early potential to improve on...

Johnson & Johnson exec Dr Sarah Siggins has signed on for ASX-listed Algorae Pharmaceuticals’ (ASX: 1AI) hunt to create drug...

Medical technology innovator Algorae Pharmaceuticals (ASX: 1AI) has identified 24 different existing drug combinations put together by a...

Algorae Pharmaceuticals (ASX: 1AI) has supercharged its bid to find and combine previously-approved drugs to create brand new medical...

Algorae Pharmaceuticals (ASX: 1AI) has made a significant breakthrough in pre-clinical testing aimed at combating the effects of dementia...

With access to a vast data library, including the biggest supercomputer in the Southern Hemisphere, Algorae Pharmaceuticals (ASX: 1AI) is...

Algorae Pharmaceuticals (ASX: 1AI) says pre-clinical testing on a combination of drugs it is developing to potentially treat dementia...

Algorae Pharmaceuticals has access to the most powerful supercomputer in the Southern Hemisphere. ASX-listed biotech Algorae Pharmaceuticals (ASX: 1AI) says its new AI-driven platform aimed at identifying previously-approved drugs it can combine to create new medical treatments will be operational as soon as this year’s third quarter. The company’s “Algorae Operating System” (AlgoraeOS) is a proprietary AI biopharmaceutical prediction platform developed in collaboration with